jdiabetesmellitus5_416.pdf 805 KB
Objective: The aim of this study is to clarify the effect of pioglitazone on serum Dipeptidyl peptidase-4 (DPP-4) level in type 2 diabetes mellitus.
Methods: Chronological changes in serum DPP-4 level were observed in 22 patients treated with pioglitazone and 15 with metformin during 12 months. Serum DPP-4 concentrations were measured by an ELISA kit. Results: In the pioglitazone group, serum DPP-4 levels were significantly increased from baseline (774 ± 198 ng/mL) with mean changes of 53 mg/mL [6.8% increase, 95% confidence interval (CI) 2 to 104, p<0.05] after 3 months and of 74 mg/mL (9.4% increase, 95% CI 21 to 126, p<0.01) after 12 months. On the other hand, serum DPP-4 levels were not changed in the metformin group. Percent change in serum DPP-4 level was significantly and positively correlated with percent change in body mass index (r=0.39, p<0.02). The association was still significant even after adjusting for age, duration of diabetes, serum creatinine, and HbAc1 (β=0.59, p<0.02).
Conclusion: The present study showed that pioglitazone, but not metformin, chronologically increased serum DPP-4 levels during 12 months.
Type 2 diabetes mellitus
Body Mass Index
Journal of diabetes & metabolism
© 2014 Kanazawa I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Faculty of Medicine